RNXT — RenovoRx, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1574094 ·
Last close
$1.04
Market Cap
$50.18M
52W High
$2.59
52W Low
$0.73
ADV30
469,219
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,066,000 | 878,000 | -3,236,000 | -3,647,000 | 12,437,000 | 10,404,000 | 3,153,000 |
| Jun 2026 | 909,000 | 766,000 | -3,349,000 | -2,911,000 | 11,472,000 | 9,479,000 | 2,493,000 |
| Mar 2026 | 563,000 | 479,000 | -3,469,000 | -3,521,000 | 13,964,000 | 12,362,000 | 2,699,000 |
| Dec 2025 | 238,000 | 210,000 | -3,523,000 | -2,941,000 | 8,095,000 | 7,024,000 | 2,673,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,866,000
Investing CF
$-71,000
Financing CF
$9,102,000
CapEx
$-2,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.31
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-67,819,000
Inventory
$383,000
Receivables
$480,000
ST Investments
—
EBIT TTM
$-13,541,000
Pretax Income TTM
$-12,286,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,976,000
EBITDA
$-13,034,000
Free Cash Flow
$-6,648,000
Enterprise Value
$44,615,116
Total Cash
$9,479,000
Total Debt
$390,000
Shares Out
48,250,592
Trailing EPS
$-0.31
Book Value
$0.15
ROE
-125.2%
ROA
-64.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,123,000 | -12,511,000 | -11,168,000 | 8,095,000 | 2,673,000 | 5,422,000 | -10,973,000 |
| Dec 2024 | 43,000 | -10,970,000 | -8,814,000 | 8,118,000 | 3,640,000 | 4,478,000 | -9,125,000 |
| Dec 2023 | 0 | -11,396,000 | -10,232,000 | 1,466,000 | 4,466,000 | -3,000,000 | -10,258,000 |
| Dec 2022 | 0 | -9,950,000 | -9,889,000 | 7,265,000 | 1,102,000 | 6,163,000 | -8,811,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,976,000
NetIncome TTM
$-12,285,000
OpCashFlow TTM
—
Assets (Latest)
$11,472,000
Forward EPS
$-0.12
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HYPR | Hyperfine, Inc. | $51.10M | $0.56 | — |
| AURX | Nuo Therapeutics, Inc. | $52.79M | $1.09 | — |
| VASO | VASO Corp | $47.52M | $0.27 | — |
| COCH | Envoy Medical, Inc. | $53.20M | $6.87 | — |
| MBOT | Microbot Medical Inc. | $46.28M | $0.69 | — |
News headlines (Yahoo Finance, 1h cache)
RenovoRx Q3 Earnings Call Highlights
2026-11-06 19:14 · Yahoo
RenovoRx (RNXT) Q3 2026 Earnings Call Transcript
2026-11-06 17:33 · Yahoo
RenovoRx Inc (RNXT) (Q3 2026) Earnings Call Highlights: Record Revenue, Expanding Commercial ...
2026-11-06 07:21 · Yahoo
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates
2026-11-06 00:00 · Yahoo
RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
2026-11-05 21:05 · Yahoo
RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
2026-10-28 12:30 · Yahoo
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
2026-10-22 12:45 · Yahoo
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
2026-10-07 12:30 · Yahoo
RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline
2026-09-02 14:39 · Yahoo
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
2026-08-25 12:30 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-17 6:30:17 | 2026-11-16 | Agah Ramtin | Exec COB, CMO | P - Purchase | 0.93 | 50000 | 46485 |